Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of ($0.36), $0.10 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $5 million versus the consensus estimate of $3.2 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.